Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 is now shown on the page. Notices about government funding lapse and an older Revision: v3.4.1 have been removed.SummaryDifference0.4%

- Check21 days agoChange DetectedA government funding lapse notice about site status was added, and the page now displays the updated revision version 3.4.1 (replacing 3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a 'Show glossary' option and updated metadata with 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' plus a new revision tag 'Revision: v3.4.0', while removing older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays Revision: v3.3.4 instead of v3.3.3. This is a minor version-label update that does not alter trial information or how users interact with the page.SummaryDifference0.0%

- Check64 days agoChange DetectedLocations are now presented under a single 'Locations' heading, and the state-specific site details (California, Florida, Georgia, Maryland) have been removed.SummaryDifference0.5%

- Check85 days agoChange DetectedRevision: v3.3.2 added and v3.3.1 removed as a minor site metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.